BARCELONA – It will likely take more than information on a tumor's tissue of origin to effectively treat carcinomas of unknown primary site (CUP), according to negative Phase III clinical trial data presented this weekend at the European Society for Medical Oncology Congress.
That realization — together with results from retrospective analyses on tumors compiled by Foundation Medicine — has at least one international team pressing forward with a Phase II trial of genomic profiling and molecularly targeted treatment in this group of carcinomas.